Upstream Bio, Inc. UPB
We take great care to ensure that the data presented and summarized in this overview for Upstream Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in UPB
Top Purchases
Top Sells
About UPB
Insider Transactions at UPB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 15
2024
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
825,000
+12.66%
|
$14,025,000
$17.0 P/Share
|
|
Oct 15
2024
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
3,609,789
+42.58%
|
-
|
|
Oct 15
2024
|
Erez Chimovits Director |
BUY
Open market or private purchase
|
Indirect |
825,000
+12.66%
|
$14,025,000
$17.0 P/Share
|
|
Oct 15
2024
|
Erez Chimovits Director |
BUY
Conversion of derivative security
|
Indirect |
3,609,789
+42.58%
|
-
|
|
Oct 15
2024
|
Ai Upstream LLC |
BUY
Conversion of derivative security
|
Direct |
4,319,410
+29.86%
|
-
|
|
Oct 15
2024
|
Ai Upstream LLC |
BUY
Open market or private purchase
|
Direct |
1,175,000
+50.0%
|
$19,975,000
$17.0 P/Share
|
|
Oct 15
2024
|
Wellington Biomedical Innovation Master Investors (Cayman) Ii L.P. |
BUY
Conversion of derivative security
|
Direct |
894,733
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
15.3M
Shares
From
7
Insiders
| Conversion of derivative security | 12.4M shares |
|---|---|
| Open market or private purchase | 2.83M shares |
Sell / Disposition
0
Shares
From
0
Insiders